BCRX

Business Context and Reporting Period

Company: BioCryst Pharmaceuticals, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2008
Business Overview: BioCryst is a biotechnology company utilizing structure-based drug design to develop small molecule pharmaceuticals for cancer, viral infections, and autoimmune diseases. The company has no commercial products and relies on collaborative agreements and government contracts for revenue.

Key Financial Metrics

Liquidity: The company reported a net cash burn rate of approximately $1.8 million per month in 2008. As of December 31, 2008, the company held $63.3 million in cash and marketable securities, which management believes is sufficient to fund operations for at least the next twelve months.

Material Changes vs. Prior Period

• Revenue Decline: Total revenues decreased by approximately 20.6% from 2007 to 2008. This was primarily driven by a $33.7 million reduction in revenue from the U.S. Department of Health and Human Services (HHS) contract for peramivir, including a $4.9 million reserve recorded for costs related to a voluntarily terminated Phase III program. This decrease was partially offset by the recognition of $26.5 million in previously deferred revenue following the termination of the Roche collaboration.
• Expense Reduction: R&D expenses decreased by $20.8 million (22.1%) due to reduced clinical and manufacturing costs for the peramivir program and the termination of the Roche collaboration. However, this was offset by the recognition of $8.2 million in previously deferred expenses related to the Roche termination.
• Improved Net Loss: Despite lower revenues, the net loss improved by $4.4 million year-over-year due to the significant reduction in R&D expenses.
• Balance Sheet Contraction: Total assets decreased by $58.0 million, largely due to a reduction in receivables from collaborations and a decrease in marketable securities.

Guidance, Outlook, and Risks

Management Commentary and Outlook

• 2009 Cash Projection: Management projects net cash use for 2009 to be between $30 million and $38 million, dependent on milestone achievements and reimbursement timing.
• Forodesine HCl: The pivotal Phase IIb trial for Cutaneous T-cell Lymphoma (CTCL) is ongoing, with enrollment exceeding 50% of the target. Interim data for Chronic Lymphocytic Leukemia (CLL) showed substantial reductions in malignant lymphocytes with a new twice-daily dosing regimen.
• Peramivir: The HHS contract ($102.6 million) remains in place, though the scope was modified to focus on Phase II studies after the Phase III i.m. program was discontinued. Shionogi (Japan partner) initiated a Phase III trial for intravenous peramivir in December 2008.
• BCX-4208: Roche terminated the license agreement in May 2008. BioCryst regained worldwide rights. A Phase II trial for psoriasis showed safety but no clinical efficacy at tested doses.

Risks and Contingencies

• HHS Funding Risk: A significant portion of revenue depends on the HHS contract. The company recorded a $4.9 million reserve for costs related to the terminated Phase III i.m. program, which are currently under discussion for reimbursement. Future funding beyond the current contract is not guaranteed.
• Dispute with Mundipharma: The company is in a dispute with partner Mundipharma regarding cost-sharing obligations for forodesine HCl. The maximum potential exposure is estimated at $2.5 million, though no amount has been accrued.
• Profitability: The company has incurred losses since inception and expects to continue incurring losses. It has no commercial products and relies on external funding.
• Regulatory and Clinical Risk: Clinical trials may fail to demonstrate efficacy or safety, and regulatory approval is uncertain. Previous FDA inspections in 1995 and 1996 cited failures to follow good clinical practices, which may lead to increased scrutiny of future trials.

Investor Verification Checklist

• HHS Contract Status: Verify the current status of the $4.9 million reserve regarding the terminated Phase III i.m. peramivir program and the likelihood of reimbursement from HHS.
• Mundipharma Dispute: Monitor the resolution of the cost-sharing dispute with Mundipharma and any potential financial impact beyond the estimated $2.5 million exposure.
• Cash Runway: Confirm the company's ability to meet its projected 2009 cash burn of $30–$38 million given the current cash balance of $63.3 million and the timing of expected HHS reimbursements.
• Clinical Trial Enrollment: Track enrollment rates for the pivotal forodesine HCl CTCL trial, as delays were noted in the summer of 2008.
• Shionogi Phase III Progress: Monitor the progress and results of the Phase III trial for peramivir initiated by Shionogi in Japan, as this is a key potential revenue driver.